Figures computed from official regulatory filings — .
Analysttarget 10.94 USD (+127%) · consensus 4.75/5 · 8 buy · 0 hold · 0 sell
Ownershipinsiders 2.55% · institutions 106.75% · short 24.7% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Savara Inc only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
157 buys52 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Parker Braden C. | Other | $148.7K | SEC |
| Lutz Robert Matthew | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lutz Robert Matthew | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | Other | $159.1K | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | Exercise | $63.2K | SEC |
| Lowrance David L | Other | $330.3K | SEC |
| Lowrance David L | Exercise | $330.3K | Unusual size | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | Other | $55.6K | SEC |
| Lowrance David L | Other | $293.6K | SEC |
| Lowrance David L | Exercise | $119.3K | SEC |
| Lowrance David L | Exercise | $55.6K | SEC |
| Lowrance David L | Exercise | $159.1K | Unusual size | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | Sell | $2.2M | Unusual size | SEC |
| Lowrance David L | Other | $63.2K | SEC |
| Lowrance David L | Exercise | $293.6K | Unusual size | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | Other | $119.3K | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lowrance David L | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |